权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP

针对 PrEP 注射吸毒者优化基于证据的艾滋病毒预防

基本信息

批准号：
10548320
负责人：
MICHAEL COPENHAVER
金额：
$ 60.56万
依托单位：
UNIVERSITY OF CONNECTICUT STORRS
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10548320
关键词：
AIDS prevention AIDS/HIV problem Acquired Immunodeficiency Syndrome Adherence Alzheimer&apos s Disease American Analgesics Area Attention Attention deficit hyperactivity disorder Behavior Behavioral Budgets Centers for Disease Control and Prevention (U.S.)Characteristics Cognitive Cognitive deficits Communities Disease Outbreaks Enrollment Evidence based intervention Exhibits Funding Funding Opportunities Goals Guidelines HIV HIV Infections HIV risk Health Health Promotion Health behavior Health behavior change Impaired cognition Incidence Individual Injectable Injecting drug user Intervention Knowledge Measurement Measures Mediator of activation protein Memory Methods Modeling Motivation Neurologic Opioid Outcome Participant Patient Self-Report Patients Performance Persons Pharmaceutical Preparations Pharmacotherapy Prevention approach Process Public Health Recovery Research Research Priority Risk Behaviors Risk Reduction Risk Reduction Behavior Science Study models Traumatic Brain Injury United States National Institutes of Health Update Work base cognitive function cognitive testing comorbidity cost cost effectiveness design evidence base executive function experience follow-up frontier future implementation high risk population information processing innovation medication compliance memory process multiphase optimization strategy opioid epidemic opioid use disorder overdose death patient population post intervention pre-exposure prophylaxis prevent primary outcome programs response secondary outcome sex skills transmission process treatment program treatment services trend

项目摘要

Framed by the multiphase optimization strategy (MOST), and building on our recent preliminary studies, we are requesting 5 years of support to conduct an optimization trial among people who inject drugs (PWID) and newly enrolled on medication for opioid use disorder (MOUD). The goal is to assess the performance of four intervention components (Attention, Executive Functioning, Memory, and Information Processing) aimed at enhancing the ability of PWID on MOUD to process and utilize evidence-based HIV prevention content, leading to improvements in Pre-Exposure Prophylaxis (PrEP) adherence and HIV risk reduction. Existing evidence-based interventions require participants to have at least moderate levels of cognitive functioning but do not acknowledge or accommodate participants with cognitive dysfunction. This is a crucial weakness as cognitive dysfunction is a common feature among PWID, and one that can directly impede their ability to process and utilize intervention content. In fact, our recent studies comparing objective and self-report cognitive assessments (e.g., NIH toolbox) show that ~67% of PWID experience substantial levels of cognitive dysfunction across tasks involving attention, executive function, memory, and information processing that, in turn, disrupt the expected intervention outcomes (e.g., medication adherence, HIV risk reduction). Our recent work also suggests that PWID newly enrolled on MOUD would benefit from an intervention approach that incorporates ‘compensatory strategies’ to accommodate their cognitive dysfunction. A number of well-established compensatory strategies have been successfully applied to other patient populations (e.g., traumatic brain injury, ADHD, Alzheimer’s/dementia) and have been identified by our team as promising intervention components that could enhance evidence-based PrEP-focused primary HIV prevention approaches targeting PWID on MOUD. To date, however, no studies have examined the potential impact and cost of incorporating such intervention components, either individually or in various combinations, in terms of enhancing PWID’s ability to process and utilize HIV prevention content. This innovative trial will be the first to use the MOST framework to optimize an evidence-based HIV prevention approach by compensating for cognitive features that are characteristic of PWID on MOUD, and maximizing PrEP adherence outcomes within real world budget constraints.

以多阶段优化策略（MOST）为框架，以我们最近的研究成果为基础